PL370274A1 - Związki pirymidynowe i kompozycje farmaceutyczne zawierające związki - Google Patents

Związki pirymidynowe i kompozycje farmaceutyczne zawierające związki

Info

Publication number: PL370274A1
Authority: PL; Poland
Prior art keywords: substituted; group; carbon atoms; aromatic heterocyclic; atom
Prior art date: 2001-10-22

Application number

PL02370274A

Other languages

English (en)

Other versions

PL215572B1 (pl

Inventor

Hitoshi Harada

Osamu Asano

Masato Ueda

Shuhei Miyazawa

Yoshihiko Kotake

Yasuhiro Kabasawa

Masahiro Yasuda

Nobuyki Yasuda

Daisuke Iida

Junichi Nakagawa

Kazuo Hirota

Makoto Nakagawa

Original Assignee

Eisai Co, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-22

Filing date

2002-10-22

Publication date

2005-05-16

2002-10-22 Application filed by Eisai Co, Ltd. filed Critical Eisai Co, Ltd.

2005-05-16 Publication of PL370274A1 publication Critical patent/PL370274A1/pl

2013-12-31 Publication of PL215572B1 publication Critical patent/PL215572B1/pl

Links

-1 Pyrimidine compound Chemical class 0.000 title abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 12
125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 4
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000000304 alkynyl group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
108050000203 Adenosine receptors Proteins 0.000 abstract 1
102000009346 Adenosine receptors Human genes 0.000 abstract 1
101150078577 Adora2b gene Proteins 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL370274A 2001-10-22 2002-10-22 Zwiazek pirymidynowy lub jego sól, kompozycja farmaceutyczna, zawierajace taki zwiazek, jej zastosowanie jako srodka do leczenia lub zapobiegania chorobom oraz zastosowanie zwiazku do wytwarzania srodka PL215572B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001324018		2001-10-22

Publications (2)

Publication Number	Publication Date
PL370274A1 true PL370274A1 (pl)	2005-05-16
PL215572B1 PL215572B1 (pl)	2013-12-31

Family

ID=19140824

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL370274A PL215572B1 (pl)	2001-10-22	2002-10-22	Zwiazek pirymidynowy lub jego sól, kompozycja farmaceutyczna, zawierajace taki zwiazek, jej zastosowanie jako srodka do leczenia lub zapobiegania chorobom oraz zastosowanie zwiazku do wytwarzania srodka

Country Status (24)

Country	Link
US (2)	US7396836B2 (pl)
EP (2)	EP1439175B1 (pl)
JP (1)	JP4462930B2 (pl)
KR (1)	KR100884025B1 (pl)
CN (1)	CN100519549C (pl)
AT (1)	ATE507217T1 (pl)
AU (1)	AU2002335536B2 (pl)
BR (1)	BR0213455A (pl)
CA (1)	CA2463284C (pl)
CY (1)	CY1112341T1 (pl)
DE (1)	DE60239884D1 (pl)
DK (1)	DK1439175T3 (pl)
ES (1)	ES2364328T3 (pl)
HU (1)	HUP0401950A3 (pl)
IL (2)	IL161493A0 (pl)
MX (1)	MXPA04003795A (pl)
NO (1)	NO327581B1 (pl)
NZ (1)	NZ532373A (pl)
PL (1)	PL215572B1 (pl)
PT (1)	PT1439175E (pl)
RU (1)	RU2288227C2 (pl)
TW (1)	TWI330183B (pl)
WO (1)	WO2003035639A1 (pl)
ZA (1)	ZA200402898B (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI330183B (pl) *	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
AU2002950853A0 (en) *	2002-08-19	2002-09-12	Fujisawa Pharmaceutical Co., Ltd.	Aminopyrimidine compound and pharmaceutical use thereof
ES2229928B1 (es) *	2003-10-02	2006-07-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) *	2003-10-03	2003-11-05	Chang Lisa C W	Pyrimidines substituted in the 2,4,6 positions and their different uses
GB0323137D0 (en)	2003-10-03	2003-11-05	Chang Lisa C W	2,4,6- Trisubstituted pyrimidines and their different uses
EP1679309A4 (en) *	2003-10-24	2007-03-28	Ono Pharmaceutical Co	ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
RU2006118325A (ru) *	2003-10-27	2007-12-10	Астеллас Фарма Инк. (Jp)	Производные пиразина и их фармацевтическое применение
MXPA06006776A (es) *	2003-12-15	2007-03-23	Almirall Prodesfarma Ag	2,6-bisheteroaril-4-aminopirimidinas como antagonistas del receptor de adenosina.
PL3002283T3 (pl)	2003-12-26	2017-10-31	Kyowa Hakko Kirin Co Ltd	Pochodne tiazolu
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
CA2562244A1 (en) *	2004-04-07	2005-10-27	Takeda Pharmaceutical Company Limited	Cyclic compounds
GB2416125A (en) *	2004-07-15	2006-01-18	Michael James Hill	Device for supplying fluid to an ear
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
GB0428514D0 (en) *	2004-12-31	2005-02-09	Prosidion Ltd	Compounds
WO2006101082A1 (ja) *	2005-03-21	2006-09-28	Eisai R & D Management Co., Ltd.	ピリミジン化合物の結晶、非晶質および製造方法
US7396928B2 (en)	2005-03-21	2008-07-08	Eisai R&D Management Co., Ltd.	Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same
US7538117B2 (en)	2005-03-21	2009-05-26	Eisai R&D Management Co., Ltd.	Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds
US20080275064A1 (en) *	2005-04-11	2008-11-06	Deborah Slee	Substituted Pyrimidines as Adenosine Receptor Antagonists
JP2008544743A (ja)	2005-05-10	2008-12-11	インターミューンインコーポレイテッド	ストレス活性化蛋白質キナーゼ系をモジュレートするためのピリドン誘導体
WO2006137527A1 (ja)	2005-06-23	2006-12-28	Kyowa Hakko Kogyo Co., Ltd.	チアゾール誘導体
ES2270715B1 (es) *	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
PT1921077T (pt)	2005-08-02	2017-10-26	Kyowa Hakko Kirin Co Ltd	Agente para tratar e/ou prevenir distúrbio do sono
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
MX2008010953A (es) *	2006-02-28	2008-09-08	Amgen Inc	Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
JP2009532507A (ja)	2006-04-04	2009-09-10	ザリージェンツオブザユニバーシティオブカリフォルニア	Ｐｉ３キナーゼアンタゴニスト
US20080009623A1 (en) *	2006-07-06	2008-01-10	Eisai R&D Management Co., Ltd.	Pyrimidine compounds
JP2009286694A (ja) *	2006-09-07	2009-12-10	Eisai R & D Management Co Ltd	５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
ES2303776B1 (es) *	2006-12-29	2009-08-07	Laboratorios Almirall S.A.	Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CA2694275A1 (en) *	2007-07-26	2009-01-29	Novartis Ag	Organic compounds
PL2203439T3 (pl)	2007-09-14	2011-06-30	Addex Pharmaceuticals Sa	1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
WO2009046448A1 (en) *	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
WO2009114870A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Kinase inhibitors and methods of use
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
CA2718983C (en)	2008-03-26	2015-12-08	Advinus Therapeutics Pvt. Ltd.	Heterocyclic compounds as adenosine receptor antagonist
MX2010012848A (es)	2008-06-03	2011-03-01	Intermune Inc	Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
CN101343253B (zh) *	2008-06-24	2011-03-16	陕西师范大学	2-氨基-4,5-二芳基嘧啶类化合物及其制备方法和药物用途
EP3009436B1 (en)	2008-07-08	2019-06-05	Intellikine, LLC	Kinase inhibitors and methods of use
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
ES2439291T3 (es)	2008-09-02	2014-01-22	Janssen Pharmaceuticals, Inc.	Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
AU2009305669A1 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
ES2401691T3 (es)	2008-11-28	2013-04-23	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
AU2010222289B2 (en)	2009-03-13	2013-07-11	Advinus Therapeutics Private Limited	Substituted fused pyrimidine compounds
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
AU2010246607B2 (en)	2009-05-12	2012-09-27	Addex Pharma S.A.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5634506B2 (ja)	2009-05-12	2014-12-03	ジャンセンファーマシューティカルズ，インコーポレイテッド	１，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
US8980899B2 (en)	2009-10-16	2015-03-17	The Regents Of The University Of California	Methods of inhibiting Ire1
US8796290B2 (en)	2009-11-09	2014-08-05	Advinus Therapeutics Limited	Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2542077A4 (en) *	2010-03-04	2013-08-21	Merck Sharp & Dohme	HEMMER OF CATECHOL-O-METHYL-TRANSFERASE AND ITS USE IN THE TREATMENT OF PSYCHOTIC DISORDER
ES2365960B1 (es) *	2010-03-31	2012-06-04	Palobiofarma, S.L	Nuevos antagonistas de los receptores de adenosina.
AU2011255218B2 (en)	2010-05-21	2015-03-12	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2810625C (en)	2010-09-13	2018-01-23	Advinus Therapeutics Private Limited	Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012039718A1 (en)	2010-09-24	2012-03-29	N30 Pharmaceuticals, Llc	Novel dihydropyrimidin-2(1h)-one compounds as neurokinin-3 receptor antagonists
JP5852665B2 (ja)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP5852666B2 (ja)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	１，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es)	2010-11-08	2015-11-30	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
US8809349B2 (en)	2011-01-10	2014-08-19	Infinity Pharmaceuticals, Inc.	Processes for preparing isoquinolinones and solid forms of isoquinolinones
CA2828483A1 (en)	2011-02-23	2012-11-01	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
CZ305457B6 (cs) *	2011-02-28	2015-09-30	Ústav organické chemie a biochemie, Akademie věd ČR v. v. i.	Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
EP2734520B1 (en)	2011-07-19	2016-09-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP2734530A1 (en)	2011-07-19	2014-05-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6029668B2 (ja)	2011-08-29	2016-11-24	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環式化合物及びその使用
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
PT2820009T (pt) *	2012-03-01	2018-04-12	Array Biopharma Inc	Inibidores de serina/treonina quinases
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502331RA (en)	2012-09-26	2015-04-29	Univ California	Modulation of ire1
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
SMT201800561T1 (it)	2012-11-01	2018-11-09	Infinity Pharmaceuticals Inc	Trattamento di cancri usando modulatori di isoforme di pi3 chinasi
EP2922543B1 (en) *	2012-11-20	2017-05-24	Merck Sharp & Dohme Corp.	Substituted pyridone derivatives as pde10 inhibitors
KR101529496B1 (ko) *	2012-12-27	2015-06-22	한국과학기술원	낮은 열팽창 계수를 갖는 신규한 폴리아미드이미드
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EP3004138B1 (en)	2013-06-05	2024-03-13	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
NZ718430A (en)	2013-10-04	2021-12-24	Infinity Pharmaceuticals Inc	Heterocyclic compounds and uses thereof
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20220038826A (ko)	2014-01-21	2022-03-29	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20200036063A (ko)	2014-01-21	2020-04-06	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3138839B1 (en) *	2014-02-14	2020-10-28	Sichuan Haisco Pharmaceutical Co., Ltd.	Pyridone or pyrimidone derivative, preparation method therefor and application thereof
DK3119397T3 (da)	2014-03-19	2022-03-28	Infinity Pharmaceuticals Inc	Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
JP6525437B2 (ja)	2014-04-02	2019-06-05	インターミューン，インコーポレイテッド	抗線維性ピリジノン
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MX390633B (es)	2015-09-14	2025-03-04	Infinity Pharmaceuticals Inc	Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
JP2017149663A (ja) *	2016-02-24	2017-08-31	株式会社Ｌｔｔバイオファーマ	過敏性腸症候群治療剤
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
SG10201912456RA (en)	2016-06-24	2020-02-27	Infinity Pharmaceuticals Inc	Combination therapies
CN110214012B (zh) *	2017-01-20	2023-05-09	艾库斯生物科学有限公司	用于治疗癌症相关疾病的唑嘧啶
WO2018184590A1 (zh) *	2017-04-07	2018-10-11	南京明德新药研发股份有限公司	作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
CN110612100B (zh) *	2017-05-05	2023-04-14	艾库斯生物科学有限公司	治疗与癌症有关疾病的喹唑啉-吡啶衍生物
US11478479B2 (en)	2018-02-16	2022-10-25	Arcus Biosciences, Inc.	Dosing with an azolopyrimidine compound
CN110240593A (zh) *	2018-03-09	2019-09-17	四川科伦博泰生物医药股份有限公司	取代芳胺化合物及其制备方法和用途
CN108314631A (zh) *	2018-04-19	2018-07-24	中国科学院昆明植物研究所	二芳基乙烯类化合物及其药物组合物和其应用
CN110655509B (zh) *	2018-06-29	2023-01-24	江苏恒瑞医药股份有限公司	2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN110684020B (zh) *	2018-07-05	2023-01-20	江苏恒瑞医药股份有限公司	2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN112423758A (zh) *	2018-07-10	2021-02-26	尼康治疗公司	腺苷受体结合化合物
WO2020011220A1 (zh) *	2018-07-12	2020-01-16	江苏恒瑞医药股份有限公司	杂芳基类衍生物、其制备方法及其在医药上的应用
CN111377873B (zh) *	2018-12-28	2023-03-28	四川科伦博泰生物医药股份有限公司	氨基嘧啶化合物及其制备方法和用途
KR20210110288A (ko) *	2018-12-28	2021-09-07	쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드	치환된 아릴 화합물, 및 이의 제조 방법 및 이의 용도
WO2020135195A1 (zh)	2018-12-28	2020-07-02	四川科伦博泰生物医药股份有限公司	氨基吡啶类化合物及其制备方法和用途
US10689374B1 (en)	2019-07-12	2020-06-23	United Arab Emirates University	Pyrimidine-thiazolidinone derivatives
US10702525B1 (en)	2019-09-04	2020-07-07	United Arab Emirates University	Pyrimidine derivatives as anti-diabetic agents
CA3171774C (en) *	2020-03-16	2025-05-20	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	AMINE DERIVATIVE PYRIMIDINE OR SUBSTITUTED PYRIDINE, RELATED COMPOSITION AND RELATED MEDICAL USE

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3029426A1 (de) *	1980-08-02	1982-03-11	Bayer Ag, 5090 Leverkusen	Gegen zwecken wirksame pour-on-formulierungen
US4725600A (en)	1984-07-13	1988-02-16	Fujisawa Pharmaceutical Co., Ltd.	Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
FR2584925B1 (fr) *	1985-07-17	1987-11-27	Bosserelle Micheline	Composition de corps gras d'origine vegetale pour usage cosmetique
US4927813A (en) *	1988-03-08	1990-05-22	Bernstein Joel E	Method and composition for treating pediculosis capitis
JPH0252360A (ja)	1988-08-15	1990-02-21	Fujitsu Ltd	電子写真感光体
PE5591A1 (es) *	1988-12-19	1991-02-15	Lilly Co Eli	Un nuevo grupo de compuestos de macrolida
US5362634A (en) *	1989-10-30	1994-11-08	Dowelanco	Process for producing A83543 compounds
US5288483A (en) *	1990-04-18	1994-02-22	The Procter & Gamble Company	Anti-lice treatment compositions
DD294255A5 (de) *	1990-05-14	1991-09-26	Adw Forschungsstelle Fuer Chemische Toxikologie,De	Verfahren zur herstellung tetrazolylsubstituierter pyrimidinderivate
US5227163A (en) *	1991-01-18	1993-07-13	Clilco, Ltd.	Lice-repellant compositions
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5539089A (en) *	1991-11-08	1996-07-23	Dowelanco	A83543 aglycones and pseudoglycones
US5227295A (en) *	1991-11-08	1993-07-13	Dowelanco	Process for isolating A83543 and its components
US5202242A (en) *	1991-11-08	1993-04-13	Dowelanco	A83543 compounds and processes for production thereof
JP2613355B2 (ja)	1992-09-28	1997-05-28	協和醗酵工業株式会社	パーキンソン氏病治療剤
US5591606A (en) *	1992-11-06	1997-01-07	Dowelanco	Process for the production of A83543 compounds with Saccharopolyspora spinosa
CA2156194C (en) *	1993-03-12	2008-01-08	Jon S. Mynderse	New a83543 compounds and process for production thereof
US5795905A (en) *	1995-06-06	1998-08-18	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
US5935966A (en) *	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
EP0888335A4 (en) *	1996-03-13	2002-01-02	Smithkline Beecham Corp	NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
US6010710A (en) *	1996-03-29	2000-01-04	Merial	Direct pour-on skin solution for antiparasitic use in cattle and sheep
US5952331A (en) *	1996-05-23	1999-09-14	Syntex (Usa) Inc.	Aryl pyrimidine derivatives
US6001981A (en) *	1996-06-13	1999-12-14	Dow Agrosciences Llc	Synthetic modification of Spinosyn compounds
FR2756177B1 (fr) *	1996-11-28	1999-01-29	Oreal	Dispersion aqueuse de vesicules resistantes a la deshydratation
TW520362B (en)	1996-12-05	2003-02-11	Amgen Inc	Substituted pyrimidine compounds and pharmaceutical composition comprising same
US6096753A (en) *	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
JP2002514196A (ja) *	1996-12-05	2002-05-14	アムジエン・インコーポレーテツド	置換ピリミジノンおよびピリドン化合物ならびに使用方法
EP0948497A2 (en) *	1996-12-05	1999-10-13	Amgen inc.	Substituted pyrimidine compounds and their use
DE19710435A1 (de) *	1997-03-13	1998-09-17	Hoechst Ag	Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
US5880076A (en) *	1997-08-04	1999-03-09	Lever Brothers Company, Division Of Conopco, Inc.	Compositions comprising glycacarbamate and glycaurea compounds
US6096326A (en) *	1997-08-15	2000-08-01	Scandinavian-American Import/Export Corporation	Skin care compositions and use
JPH11188484A (ja)	1997-12-25	1999-07-13	Nkk Corp	多段研削バリ取り装置
EP1300147A1 (en) *	1998-01-05	2003-04-09	Eisai Co. Ltd	Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus
JP3990061B2 (ja)	1998-01-05	2007-10-10	エーザイ・アール・アンド・ディー・マネジメント株式会社	プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤
US6235754B1 (en) *	1998-01-30	2001-05-22	American Cyanamid Company	Methods and compositions for protecting animals and humans against attack and infestation by arthropod and helminth parasites
DE19823397B4 (de) *	1998-05-26	2011-07-28	Bayer CropScience AG, 40789	Verwendung von Spinosynen zum Einsatz als Bodeninsektizide
ATE274510T1 (de) *	1998-06-19	2004-09-15	Chiron Corp	Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) *	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
UA65624C2 (uk) *	1998-07-02	2004-04-15	Елі Ліллі Енд Компані	Препарат для догляду за волоссям (варіанти) та спосіб боротьби з педикульозним ураженням людини із застосуванням спінозину (варіанти)
TWI241298B (en)	1998-09-25	2005-10-11	Mitsubishi Chem Corp	Pyrimidone derivatives
JP2000126489A (ja)	1998-10-21	2000-05-09	Purotonikusu Kenkyusho:Kk	糸又は布と接触するミシン用部品
NZ516260A (en)	1999-07-02	2004-08-27	Eisai Co Ltd	Fused imidazole compounds and remedies for diabetes mellitus
HRP20020673A2 (en) *	2000-02-25	2004-12-31	Hoffmann La Roche	Adenosine receptor modulators
WO2001070727A1 (en)	2000-03-23	2001-09-27	Sanofi-Synthelabo	2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
EP1136482A1 (en)	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
EP1136486A1 (en)	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives
US7189717B2 (en) *	2000-04-26	2007-03-13	Eisai Co., Ltd.	Medicinal compositions promoting bowel movement
MXPA03001136A (es)	2000-08-11	2003-06-24	Eisai Co Ltd	Compuesto de 2-aminopiridina y uso medico del mismo.
WO2002020495A2 (en) *	2000-09-06	2002-03-14	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
AP2003002762A0 (en) *	2000-09-15	2003-03-31	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors
WO2002024893A2 (en)	2000-09-19	2002-03-28	Chiron Corporation	CHARACTERIZATION OF THE GSK-3β PROTEIN AND METHODS OF USE THEREOF
MY130778A (en)	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
TWI330183B (pl)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
TWI301834B (en)	2001-10-22	2008-10-11	Eisai R&D Man Co Ltd	Pyrimidone compound and pharmaceutical composition including the same
AU2002950853A0 (en)	2002-08-19	2002-09-12	Fujisawa Pharmaceutical Co., Ltd.	Aminopyrimidine compound and pharmaceutical use thereof
US7538117B2 (en)	2005-03-21	2009-05-26	Eisai R&D Management Co., Ltd.	Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds
US7396928B2 (en)	2005-03-21	2008-07-08	Eisai R&D Management Co., Ltd.	Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same

2002
- 2002-10-21 TW TW091124227A patent/TWI330183B/zh not_active IP Right Cessation
- 2002-10-22 EP EP02802050A patent/EP1439175B1/en not_active Expired - Lifetime
- 2002-10-22 IL IL16149302A patent/IL161493A0/xx unknown
- 2002-10-22 MX MXPA04003795A patent/MXPA04003795A/es active IP Right Grant
- 2002-10-22 NZ NZ532373A patent/NZ532373A/en not_active IP Right Cessation
- 2002-10-22 PL PL370274A patent/PL215572B1/pl not_active IP Right Cessation
- 2002-10-22 HU HU0401950A patent/HUP0401950A3/hu unknown
- 2002-10-22 RU RU2004115495/04A patent/RU2288227C2/ru not_active IP Right Cessation
- 2002-10-22 DE DE60239884T patent/DE60239884D1/de not_active Expired - Lifetime
- 2002-10-22 AT AT02802050T patent/ATE507217T1/de active
- 2002-10-22 EP EP10173222A patent/EP2246344A1/en not_active Withdrawn
- 2002-10-22 ES ES02802050T patent/ES2364328T3/es not_active Expired - Lifetime
- 2002-10-22 KR KR1020047005915A patent/KR100884025B1/ko not_active Expired - Fee Related
- 2002-10-22 DK DK02802050.1T patent/DK1439175T3/da active
- 2002-10-22 WO PCT/JP2002/010952 patent/WO2003035639A1/ja not_active Ceased
- 2002-10-22 JP JP2003538155A patent/JP4462930B2/ja not_active Expired - Fee Related
- 2002-10-22 CN CNB028209311A patent/CN100519549C/zh not_active Expired - Fee Related
- 2002-10-22 AU AU2002335536A patent/AU2002335536B2/en not_active Ceased
- 2002-10-22 CA CA2463284A patent/CA2463284C/en not_active Expired - Fee Related
- 2002-10-22 BR BR0213455-1A patent/BR0213455A/pt not_active IP Right Cessation
- 2002-10-22 US US10/492,905 patent/US7396836B2/en not_active Expired - Fee Related
- 2002-10-22 PT PT02802050T patent/PT1439175E/pt unknown
2004
- 2004-04-16 ZA ZA200402898A patent/ZA200402898B/xx unknown
- 2004-04-19 NO NO20041580A patent/NO327581B1/no not_active IP Right Cessation
- 2004-04-19 IL IL161493A patent/IL161493A/en not_active IP Right Cessation
2008
- 2008-03-24 US US12/054,337 patent/US20090030023A1/en not_active Abandoned
2011
- 2011-07-11 CY CY20111100672T patent/CY1112341T1/el unknown

Also Published As

Publication number	Publication date
US20050004149A1 (en)	2005-01-06
PT1439175E (pt)	2011-07-08
JPWO2003035639A1 (ja)	2005-02-10
NO327581B1 (no)	2009-08-24
CN1575290A (zh)	2005-02-02
ATE507217T1 (de)	2011-05-15
EP1439175A1 (en)	2004-07-21
KR100884025B1 (ko)	2009-02-17
CA2463284C (en)	2010-10-19
DE60239884D1 (de)	2011-06-09
ES2364328T3 (es)	2011-08-31
DK1439175T3 (da)	2011-07-18
HUP0401950A2 (hu)	2005-01-28
IL161493A0 (en)	2004-09-27
US7396836B2 (en)	2008-07-08
RU2004115495A (ru)	2005-04-10
EP2246344A1 (en)	2010-11-03
HUP0401950A3 (en)	2010-06-28
ZA200402898B (en)	2006-03-29
EP1439175A4 (en)	2004-12-29
CN100519549C (zh)	2009-07-29
PL215572B1 (pl)	2013-12-31
CA2463284A1 (en)	2003-05-01
TWI330183B (pl)	2010-09-11
KR20040053191A (ko)	2004-06-23
WO2003035639A1 (en)	2003-05-01
EP1439175B1 (en)	2011-04-27
MXPA04003795A (es)	2004-07-30
US20090030023A1 (en)	2009-01-29
CY1112341T1 (el)	2015-12-09
IL161493A (en)	2010-04-29
JP4462930B2 (ja)	2010-05-12
NZ532373A (en)	2007-02-23
NO20041580L (no)	2004-07-22
AU2002335536B2 (en)	2008-11-13
BR0213455A (pt)	2004-10-19
RU2288227C2 (ru)	2006-11-27

Legal Events

Date	Code	Title	Description
2014-11-28	LAPS	Decisions on the lapse of the protection rights	Effective date: 20131022

Publication	Publication Date	Title
ZA200402898B (en)	2006-03-29	Pyrimidine compound and medicinal composition thereof
IL153995A0 (en)	2003-07-31	2-aminopyridine derivatives and pharmaceutical compositions containing the same
HUP0303183A2 (hu)	2003-12-29	Gerinctelen kártevőírtó hatású heterociklusos diamidszármazékok, azokat tartalmazó készítmények és alkalmazásuk
NO179675C (no)	1996-11-27	Pyrimidin-nukleosidderivater og farmasöytisk preparat inneholdende disse
WO2003035640A1 (en)	2003-05-01	Pyrimidone compounds and pharmaceutical compositions containing the same
IL154709A0 (en)	2003-10-31	Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
TW200716528A (en)	2007-05-01	Cyclopropanecarboxamide derivatives
MY169840A (en)	2019-05-16	Isoxazolines for controlling invertebrate pests
DK289888D0 (da)	1988-05-27	2-substitueret-e-kondenserede oe1,2,4,aatriazolooe1,5-caapyrimidiner, farmaceutiske praeparater og anvendelser deraf
MXPA05010824A (es)	2005-12-05	Compuestos biciclicos como antagonistas del receptor nr2b.
CY1106343T1 (el)	2011-10-12	Παραγωγα νικοτιναμιδιου χρησιμα σαν pde4 αναστολεις
MXPA02011417A (es)	2003-04-25	1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
DE69324403D1 (de)	1999-05-20	Herbizide 2,6-substituierte Pyridine
WO2003028459A8 (de)	2004-04-29	Nicotinsäure-heterocyclyl-amide und analogue pyrimidin-derivate als schädlingsbekämpfungsmittel
TW200612920A (en)	2006-05-01	Novel imidazolidine derivatives
TW200613297A (en)	2006-05-01	Pyrazole derivatives
KR970069989A (ko)	1997-11-07	피리딘-2,3-디카르복실산 디아미드 유도체 및 유효성분으로 상기 유도체를 함유하는 제초제
EP0630893A4 (en)	1995-04-05	N, N'-DISUBSTITUTED AMIDE DERIVATIVES.
HUP0000366A2 (hu)	2000-12-28	Eljárás heterociklusos vegyületek előállítására
PT1492792E (pt)	2006-08-31	Derivados de 3-heteroaril-3,5-di-hidro-4-oxo-4h-piridazino(4, 5-b) ao em terapeutica.
WO1999065864A3 (de)	2003-05-22	Geminal substituierte amine
ATE500241T1 (de)	2011-03-15	Phenyl- und pyridyl-piperidine mit tnf-wirkung
TH65444A (th)	2004-12-13	สารประกอบอินทรีย์
NO20003945L (no)	2000-10-03	N-acyl sykliske aminderivater